Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$2.3 million.

  • Anika Therapeutics' Free Cash Flow rose 31.13% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $648,000, marking a year-over-year increase of 180.20%. This contributed to the annual value of -$2.3 million for FY2024, which is 67.69% up from last year.
  • Latest data reveals that Anika Therapeutics reported Free Cash Flow of -$2.3 million as of FY2024, which was up 67.69% from -$7.2 million recorded in FY2023.
  • Anika Therapeutics' 5-year Free Cash Flow high stood at $11.4 million for FY2020, and its period low was -$7.2 million during FY2023.
  • Moreover, its 3-year median value for Free Cash Flow was -$3.1 million (2022), whereas its average is -$4.2 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 194.56% in 2022, then skyrocketed by 67.69% in 2024.
  • Yearly analysis of 5 years shows Anika Therapeutics' Free Cash Flow stood at $11.4 million in 2020, then slumped by 71.55% to $3.3 million in 2021, then crashed by 194.56% to -$3.1 million in 2022, then plummeted by 134.48% to -$7.2 million in 2023, then surged by 67.69% to -$2.3 million in 2024.